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Abstract
Pain is an experience that affects many people worldwide and is associated with higher mortality and lower quality of life.
Cannabinoid, cannabis, and cannabis-based medicines (CBMs) are thought to reduce pain, but a proliferation of different products
has led to variability in trials, creating a challenge when determining the assessment of efficacy in systematic reviews. We will
conduct 2 systematic reviews commissioned by the International Association for the Study of Pain Task Force on the use of
cannabinoids, cannabis, and CBMs for pain management: first, an overview review of systematic reviews to summarise the
evidence base and second, a systematic review of randomised controlled trials of cannabinoids, cannabis, and CBMs. In these
reviewswewill determine the harm and benefit of CBM from the current literature andwill interpret the findings in light of the quality of
evidence and reviews included. We will search online databases and registries in any language for systematic reviews and
randomised controlled trials. We will include studies that evaluate any cannabinoid or CBM vs any control for people with acute and
chronic pain. Our primary outcomes for both reviews are the number of participants achieving (1) a 30% and (2) 50% reduction in
pain intensity, (3) moderate improvement, and (4) substantial improvement. A number of secondary outcomemeasures will also be
included. We will assess risk of bias and quality of evidence. We will analyse data using fixed and random effect models, with
separate comparators for cannabis and CBMs. Prospero ID (CRD42019124710; CRD42019124714).
Keywords: Cannabinoids, Cannabis, Meta-analysis, Pain, Protocol, Systematic review, Overview
1. Introduction
In 2018, the International Association for the Study of Pain
established a Task Force on the use of cannabis and
cannabinoid-based medicinal products for pain management,
broadly conceptualised. It has 4 Work Packages focused on (1)
basic science, including medicinal chemistry, compound
classification, pharmacology, and assessment of efficacy in
preclinical studies, (2) evidence synthesis on clinical efficacy and
where possible effectiveness, (3) evidence synthesis on
potential harms—going beyond adverse events reported in
randomized controlled clinical trials to include harms reported in
other study designs,12,23 and (4) the societal impact including
changing policy and political practice. This review is part of the
second Work Packages and is focused on summarizing the
evidence for both the efficacy and adverse events as measured
primarily within individual randomized controlled trials (RCTs) of
cannabinoids, cannabis, and cannabis-based medicines
(CBMs).
Pain is a common symptom of a wide variety of common
conditions and the primary reason most patients seek health
care.21 Globally, tension-type headache is the primary cause of
morbidity, with musculoskeletal and neuropathic pain also
common.32 The incidence of chronic pain is routinely estimated
to be between 11% and 40% of the population, with as many as
10% reporting severe pain.4,11 Chronic pain has a larger impact
on quality of life than other common chronic conditions,40 and
there is a graded increase in mortality as pain severity increases in
older adults, especially for patients who report walking
disability.38,39
Pharmacological treatment of pain can provide considerable
improvements, including reduced pain intensity and increased
function. However, this benefit is only reported by a minority of
patients,26 with the exception of patients reporting acute pain
after surgery and cancer pain.27 For most other patients reporting
primarily chronic pain, most pharmacological interventions do not
improve quality of life, meaningfully reduce pain intensity, or
improve physical functioning.26 These findings all relate to adult
data. For children and adolescents, there are little data of any kind
to guide practice.8,9
Cannabis plant material typically contains over 450 different
compounds, with over 100 classified as phytocannabinoids. The
2 phytocannabinoids that have been most studied to date in the
context of medical research are delta 9-tetrahydrocannabinol
(THC, the main psychoactive constituent) and cannabidiol (CBD).
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Preclinical data support an influence of cannabinoids and
modulators of the body’s own endogenous cannabinoids
(endocannabinoids) on nociception.30,41,48 The analgesic effects
of THC are mediated primarily through agonism of cannabinoid1
(CB1) and cannabinoid2 (CB2 receptors), with the former being
chiefly responsible for its psychoactive effects. By contrast, CBD
does not activate CB1 or CB2 receptors and appears to have
a complex pharmacology with activity at a number of different
targets that include, but are not limited to: 5-HT1A receptor
agonism, negative allosteric modulation of CB1, GPR55 antag-
onism, TRPV1 activation, PPARg activation, and reuptake
inhibition (eg, anandamide and adenosine).3,18,20,31,34,35,43
The content of THC and CBD in medical cannabis is highly
variable, with typical ranges from 1% to 22% THC and 0.05% to
9% CBD. By contrast, the THC/CBD concentration in THC/CBD
oromucosal spray (nabiximols) and the THC content in plant-
derived and synthetic THC are standardised. There is consider-
able research interest in the use of medicinal cannabis and
CBMs, including for pain. As such, a high-quality review of the
literature is needed at this time to assess the quality of evidence
and to provide recommendations to clinicians and policymakers
on how beneficial cannabinoids, cannabis, and CBM are for
people with pain, and what adverse events are associated with
them. Table 1 (Ref. 15) provides a summary of current
terminology, definitions, and typical products.
2. Aims and objectives
In this protocol, we outline 2 systematic reviews. First, we aim to
conduct an overview review of systematic reviews and second, to
conduct a systematic review of RCTs. These 2 reviews will be
individually published.
The aim of the overview review is to provide a comprehensive
summary of the evidence, including an estimate of the therapeutic
efficacy and summary of the adverse events of cannabinoid and
CBM for pain management. Our goal is to review all published
systematic reviews that have attempted to summarise the
evidence for efficacy and adverse events reported in systematic
reviews evaluating the evidence from RCTs. We recognise the
existence ofmultiple reviews of the primary literature, andwe note
that different reviews have produced different conclusions. Our
aim is to provide an authoritative overview of these reviews and
help in understanding the variability across reviews with a focus
on their quality. We will assess each review’s quality, scope, and
reported result against the highest reporting standards.
The aim of the systematic review of RCTs is to provide
a comprehensive summary of the evidence from primary RCTs of
cannabinoids, cannabis, and CBMs in clinical acute and chronic
pain management, across the lifespan. We will (1) provide estimates
of the efficacy and adverse events from trial data and (2) provide an
assessment of the risk of bias and quality of evidence.
3. Methods
3.1. Protocol registration
The protocols for these 2 systematic reviews are registered on
Prospero (overview of systematic reviews Prospero ID
CRD42019124710; systematic review for RCTs Prospero ID
CRD42019124714). We have followed the Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols.22 This
protocol has used the Cochrane Pain, Palliative, and Supportive
Care review group template, which are used in a number of other
Cochrane Reviews (including, but not limited to Refs. 25 and 47).
3.2. Type of participants
Across both reviews, we will include people with acute or chronic
pain. Chronic pain is defined as continuous or recurrent pain
lasting for longer than 3 months. Acute or chronic pain includes,
but is not limited to, the following conditions: abdominal pain,
cancer pain, headache, migraine, acute or chronic neuropathic
pain, acute or chronic musculoskeletal pain, pelvic pain,
menstrual pain, acute postoperative pain, or any other form of
pain. We will include people with pain across the lifespan
(including children) and reviews of trials conducted in any setting,
in any part of the world. However, we will exclude trials of people
undergoing experimental pain procedures. For the review of
RCTs only, trials must include 30 participants/arm post-
treatment. Trials that include smaller sample sizes are more likely
to produce larger effects.6,42
3.3. Types of interventions and comparators
We will include any type of cannabinoid product, natural or
synthetic, delivered by any route of administration in both reviews.
We will include any control, including placebo or active pain
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therapy, pharmacological or nonpharmacological. Trials that
deliver cannabinoids, cannabis, or CBMs in addition to other
drugs will also be included. We will only include systematic
reviews and trials that have the intention of decreasing pain
intensity in participants.
3.4. Types of outcomes
The primary and secondary outcomes will be as follows for both
reviews:
3.4.1. Primary outcomes
We will extract the following 4 primary outcomes:
(1) The proportion of people with at least 30% pain intensity
reduction;
(2) The proportion of people with at least 50% pain intensity
reduction;
(3) Moderate improvement defined by IMMPACT7; and
(4) Substantial improvement defined by IMMPACT.7
3.4.2. Secondary outcomes
Wewill extract the following secondary outcomes for trials, where
available:
(1) Continuous assessments of pain intensity (eg, using a numer-
ical rating scale or visual analogue scale);
(2) The proportion of people who decreased pain frommoderate/
severe to mild;
(3) Disability or physical functioning measures;
(4) Emotional functioning (eg, anxiety and depression);
(5) Carer Global Impression of Change;
(6) Quality of life as defined by validated scales;
(7) The number of adverse events: Adverse events will include
measures of harm, including withdrawal due to serious
adverse events, withdrawal due to adverse events,
patients reporting any adverse event, and particular
adverse events (especially central nervous system and
cardiovascular adverse events). Following the PRISMA
Harms Checklist, we will describe how adverse events
were addressed, how they were reported, and over what
time period the harm was experienced49;
(8) Requirement for rescue analgesia;
(9) Sleep duration and quality; and
(10) Onset and duration of analgesic effects (when relevant in
acute pain trials).
3.5. Search method and study selection
For the overview review, we will search PubMed, EMBASE,
DARE, and theCochraneControlled Register of Trials (CENTRAL)
for systematic reviews of cannabinoids, cannabis, and CBMs for
people with pain. For the review of RCTs, we will search PubMed,
EMBASE, and CENTRAL (see Appendix 1 for search strategies,
available at http://links.lww.com/PR9/A42).
For both reviews, 2 authors will independently sift the titles and
abstracts identified in the database search. A third author will
resolve any disagreements. We will include any peer-reviewed
publication that investigates the therapeutic effects of any
cannabinoid preparation, given by any route of administration,
for relief of pain, compared with placebo or a different active
treatment. We will not include trials based on the measures they
report. We will not seek the unpublished literature or conference
abstracts. However, we will search online trial registry databases
Table 1
Description of types of CBMs.*
Term Definition Examples/typical products
(Herbal) Cannabis, marijuana The whole plant or parts or material from the plant
(eg, flowers, buds, resin, and leaves).
Cannabis sativa and hashish
Medical or medicinal cannabis The terms “medical/medicinal cannabis” (or
“medical/medicinal marijuana”) are used for
cannabis plants, plant material, or full plant extracts
used for medical purposes.
Bedrocan, Bedrobinol, and Tilray 10THC/10CBD
Cannabinoids Cannabinoids are biologically active constituents of
cannabis, or synthetic compounds, usually having
affinity for, and activity at, cannabinoid receptors.
THC, CBD, CP55,940, WIN55,212‐2, and HU210
Phytocannabinoid A cannabinoid found in the cannabis plant or
purified/extracted from plant material.
THC and CBD
Endocannabinoid An endogenous ligand found in the body of humans
and other animals and which has affinity for, and
activity at, cannabinoid receptors.
Anandamide and 2-AG
Endocannabinoid system modulators In addition to individual phytocannabinoids,
cannabis-derived or cannabis-based medicines,
and cannabis extracts, other pharmacological
approaches under development for manipulation of
the endocannabinoid system include selective
synthetic cannabinoid receptor agonists or
antagonists, and inhibitors of the catabolism (eg,
fatty acid amide hydrolase [FAAH] inhibitors) or
reuptake of endocannabinoids.
PF-04457845, URB597, and rimonabant
Cannabis-based (or cannabis-derived)
medicines
Registered, regulatory body approved medicinal
cannabis extracts with defined and standardized
phytocannabinoid content, particularly THC and
THC/CBD.
Nabiximols (Sativex), dronabinol, marinol, and
Epidiolex
* The table adapted from Ref. 15.
CBD, cannabidiol; CBM, cannabis-based medicine.
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including clinicaltrials.gov, EudraCT, and Prospero where appro-
priate. We will not restrict the searches on language or date. We
will conduct reference and citation searches of included reviews
and trials.
For the systematic review of RCTs, where possible, we will
match included RCTs to their trial registry identifier. We will
include trials registered but yet to report as unpublished in “on-
going studies and awaiting classification.” These studies will not
be included in the analyses andwill be described separately to the
included studies. We will assess and, if possible, describe any
reasons for nonpublication.
3.6. Data extraction
For both reviews, 2 authors will independently extract data from
included trials. A third author will resolve any disagreements. We
will extract the following data from each study:
(1) Review/study characteristics, eg, design, participants en-
rolled, age, sex, pain condition, enrolment method, and
inclusion/exclusion criteria.
(2) Intervention and comparator characteristics, eg, type of
cannabinoid, dose, route of administration, and comparator.
(3) Outcomes—wewill extract any outcomes listed in the primary
and secondary outcomes of this review. We will extract
outcomes at short term (between up to 7 days after
administration) and long term (greater than or equal to 7 days
after administration).
3.7. Validity assessment
For the overview review, we will conduct additional validity
checks. For reviews and results of reviews in pain to be valid,
a number of other criteria will be taken into account, and we will
also evaluate these points in the assessment of the systematic
reviews. This will be done in duplicate, and disagreements will be
discussed and arbitrated by a third author. These include the
following:
(1) Did the review use a defined diagnostic criterion for pain
conditions?
(2) Did the reviews include only studies in which patients made
their own assessment of pain? This is important because
research has found that professionals disagree with patient
assessments and often significantly underestimate pain.36
(3) Did the reviews use studies with defined minimum pain
intensity? It is usual to define a minimal pain intensity of
moderate or severe pain, as only mild pain can be acceptable
to patients, and reduce the sensitivity of a trial to demonstrate
an analgesic effect from an intervention.
(4) Did the reviews examine study size as a confounding factor in
any analysis of efficacy? There is increasing evidence of the
importance of small trial size, both because of random
chance,2,28,44 and as an important source of bias.5,6,10,19,29
Systematic reviews have been criticised for being over-
confident of results with inadequate data.1,33,46
(5) Did the review examine susceptibility to publication bias?
Statistical tests for the presence of publication bias have been
shown to be unhelpful.45 For each review with dichotomous
numerical data, we will assess the possible effects of
publication bias by calculating the number of participants in
studies with zero effect (relative risk of 1, or risk difference of
zero) needed to give a number needed to treat (NNT) too high
to be clinically relevant.24 In this case, we will use as a cutoff
for clinical relevance, an NNT of 10 or above.
3.8. Risk of bias
For the systematic review of RCTs, 2 authors will independently
assess the risk of bias of included studies using the Cochrane risk
of bias tool,16 and a third author will resolve disagreements. We
will assess the following risk of bias categories, making judge-
ments using the following criteria. This section uses suggested
wording from the Cochrane Pain, Palliative, and Supportive Care
review group template, which are used in a number of other
Cochrane Reviews (including, but not limited to Refs. 25 and 47).
(1) Random sequence generation (checking for possible
selection bias): We will assess the method used to generate
the allocation sequence as low risk of bias (any truly random
process, eg, random number table; computer random
number generator); unclear risk of bias (insufficient detail
about the method of randomisation to be able to judge the
generation as “low” or “high” risk of bias). Studies using
a nonrandom process (eg, odd or even date of birth; hospital
or clinic record number) will be excluded.
(2) Allocation concealment (checking for possible selection
bias): The method used to conceal allocation to interven-
tions before assignment determines whether intervention
allocation could have been foreseen in advance of, or during
recruitment, or changed after assignment. We will assess
the methods as low risk of bias (eg, telephone or central
randomisation; consecutively numbered sealed opaque
envelopes); unclear risk of bias (insufficient detail about
the method of randomisation to be able to judge the
generation as “low” or “high” risk of bias). Studies that do not
conceal allocation (eg, open list) will be excluded.
(3) Blinding of participants and personnel (checking for possible
performance bias): We will assess the methods used to
blind study participants and personnel from knowledge of
which intervention a participant received. We will assess the
methods as low risk of bias (no blinding or incomplete
blinding, but the review authors judge that the outcome was
not likely to be influenced by lack of blinding, or blinding of
participants and key study personnel ensured, and unlikely
that the blinding could have been broken); unclear risk of
bias (insufficient detail about themethod of randomisation to
be able to judge the generation as “low” or “high” risk of bias,
or the study does not address this outcome); or high risk of
bias (no blinding or incomplete blinding, and the outcome
was likely to be influenced by lack of blinding, or blinding of
key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome
was likely to be influenced by lack of blinding).
(4) Blinding of outcome assessment (checking for possible
detection bias): We will assess the methods used to blind
study participants and outcome assessors from knowledge
of which intervention a participant received. We will assess
the methods as low risk of bias (no blinding of outcome
assessment, but the review authors judge that the outcome
measurement was not likely to be influenced by lack of
blinding, or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken); unclear
risk of bias (insufficient detail about themethod of blinding to
be able to judge the generation as “low” or “high” risk of
bias, or the study does not address this); high risk of bias (no
blinding of outcome assessment, and the outcome
measurement was likely to be influenced by lack of blinding,
or blinding of outcome assessment, but likely that the
blinding could have been broken, and the outcome
measurement was likely to be influenced by lack of blinding).
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(5) Incomplete outcome data (checking for possible attrition bias
due to the amount, nature, and handling of incomplete outcome
data): We will assess the methods used to deal with incomplete
data as low risk (no missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing
outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups; missing
data have been imputed using “baseline observation carried
forward” analysis); unclear risk of bias (insufficient reporting of
attrition/exclusions to permit a judgement of “low risk” or “high
risk” [eg, number randomised not stated, no reasons formissing
data provided, or the study did not address this outcome]); high
risk of bias (reason for missing outcome data is likely to be
related to true outcome, with either imbalance in numbers or
reasons for missing data across intervention groups; “as-
treated” analysis performed with substantial departure of the
intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation).
(6) Selective reporting (checking for reporting bias):Wewill assess
reporting biases because of selective outcome reporting. We
will judge studies as low risk of bias (the study protocol is
available and all of the study’s prespecified [primary and
secondary] outcomes that are of interest in the review have
been reported in the prespecifiedway; the study protocol is not
available, but it is clear that the published reports include all
expected outcomes, including those that were prespecified
[convincing text of this naturemaybeuncommon]); unclear risk
of bias (insufficient information available to permit a judgement
of “low risk” or “high risk”); high risk of bias (not all of the study’s
prespecified primary outcomes have been reported; one or
more primary outcomes have been reported using measure-
ments, analysis methods, or subsets of the data (eg,
subscales) that were not prespecified; one or more reported
primary outcomes were not prespecified (unless clear justifi-
cation for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review
have been reported incompletely so that they cannot be
entered in a meta-analysis; the study report failed to include
results for a key outcome that would be expected to have been
reported for such a study).
3.9. Assessment of methodological quality of
included reviews
For the overview review, we will assess each included review
using AMSTAR-2, which determines rigorous methodological
review quality.37 Two authors will assess each review using the
criteria, and a third author will resolve disagreements. We will also
assess how each review compares with Cochrane assessments
of risk of bias,16 together with other methodological issues, such
as imputation bias, or small size effects.
Table 2
Definitions of hierarchy of groups and EPOC criteria.
Group Definition GRADE of evidence (EPOC 2015)
1 Drugs and doses for which Cochrane Reviews found
no information (very low quality evidence).
Very low quality: this research does not provide
a reliable indication of the likely effect. The
likelihood that the effect will be substantially
different* is very high.
2 Drugs and doses for which Cochrane Reviews found
inadequate information: fewer than 200
participants in comparisons, in at least 2 studies
(very low quality evidence).
Very low quality: this research does not provide
a reliable indication of the likely effect. The
likelihood that the effect will be substantially
different* is very high.
3 Drugs and doses for which Cochrane Reviews found
evidence of effect, but where results were
potentially subject to publication or other biases. We
considered the number of additional participants
needed in studies with zero effect (relative benefit of
one) required to change the NNT for at least 50%
maximum pain relief to an unacceptably high level
(in this case, the arbitrary NNT of 10) (Moore
et al.24). With fewer than 400 participants
(equivalent to 4 studies with 100 participants per
comparison, or 50 participants per group), we
considered the results to be susceptible to
publication bias and therefore unreliable (low-
quality evidence). We also considered data analyses
with low numbers and subject to potential major
bias to also be unreliable (low-quality evidence).
Low quality: this research provides some indication
of the likely effect. However, the likelihood that it will
be substantially different* is high.
4 Drugs and doses for which Cochrane Reviews found
evidence of no effect (high-quality evidence) or no
evidence of effect (moderate-quality evidence):
more than 200 participants in comparisons, but
where there was no statistically significant
difference from placebo.
High quality: this research provides a very good
indication of the likely effect. The likelihood that the
effect will be substantially different* is low.
Moderate quality: this research provides a good
indication of the likely effect. The likelihood that the
effect will be substantially different* is moderate.
5 Drugs and doses for which Cochrane Reviews found
evidence of effect, where results were reliable and
not subject to potential publication bias (high-
quality evidence).
High quality: this research provides a very good
indication of the likely effect. The likelihood that the
effect will be substantially different* is low.
* Substantially different: a large enough difference that it might affect a decision.
NNT, number needed to treat.
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3.10. Quality of the evidence (GRADE)
This section uses suggested wording from the Cochrane Pain,
Palliative, and Supportive Care review group template, which are
used in a number of other Cochrane Reviews (including, but not
limited to Refs. 25 and 47).
For both reviews, we will use GRADE to assess the quality of
the evidence in each review. Two review authors will rate the
quality of each outcome. The GRADE approach uses 5
considerations (study limitations, unexplained heterogeneity
and inconsistency of effect, imprecision, indirectness, and
publication bias) to assess the quality of the body of evidence
for each outcome. The GRADE system uses the following criteria
for assigning the grade of evidence:
(1) High: we are very confident that the true effect lies close to that
of the estimate of the effect;
(2) Moderate: we are moderately confident in the effect estimate;
the true effect is likely to be close to the estimate of effect, but
there is a possibility that it is substantially different;
(3) Low: our confidence in the effect estimate is limited; the true
effect may be substantially different from the estimate of the
effect;
(4) Very low: we have very little confidence in the effect estimate;
the true effect is likely to be substantially different from the
estimate of effect.
Factors that may decrease the quality level of a body of
evidence are as follows:
(1) Limitations in the design and implementation of available
studies suggesting high likelihood of bias;
(2) Indirectness of evidence (indirect population, intervention,
control, and outcomes);
(3) Unexplained heterogeneity or inconsistency of results (in-
cluding problems with subgroup analyses);
(4) Imprecision of results (wide confidence intervals); and
(5) High probability of publication bias.
We will decrease the grade rating by one (21) level (from high
to moderate quality of evidence), 2 (22) levels (to low-quality
evidence), or 3 (23) levels (to very low quality of evidence).
Outcomes can be downgraded a maximum of 3 levels using the
following criteria:
(1) Serious (21) or very serious (22) study limitations.
(2) Some (21) or considerable (22) inconsistency of results.
(3) Some (21) or considerable (22) uncertainty about directness.
(4) Some (21) or considerable (22) imprecision.
(5) Some (21) or considerable (22) probability of reporting bias.
There may be circumstances where the overall rating for
a particular outcome needs to be adjusted as recommended by
GRADE guidelines.14 Examples might be where there are so few
participants that the results are highly susceptible to the random
play of chance, or if studies use last observation carried forward
imputation in circumstances where there are substantial differ-
ences in adverse event withdrawals. In circumstances such as
this, there would be little confidence in the result, which would be
downgraded 3 levels, to very low quality. In circumstances where
there are no data reported, we will report the level of evidence as
very low quality.13
3.11. “Summary of findings” tables
For both reviews, we will produce 2 main “summary of findings”
tables; cannabis vs control, and CBMs (to include individual
cannabinoids) vs control. Furthermore, we will rate the quality for
all subgroup analyses conducted and describe reasons for
downgrading. We will include the following 7 outcomes: 50%
pain reduction, 30% pain reduction, moderate improvement,
substantial improvement, adverse events, physical functioning,
and emotional functioning.
3.12. Data synthesis
For the overview review, we will evaluate the strengths and
weaknesses of systematic reviews of cannabinoids in treating
pain of any source. We plan to show this in a tabular form. We will
only analyse evidence that falls into the EPOC groups 4 and 5
(Table 2). Where enough data are available, we will combine data
from systematic reviews into a meta-analysis to investigate our
primary or secondary outcomes.
For the review of RCTs, we will combine data in meta-analyses
where possible. Both reviews will conduct the same analyses and
subgroup analyses where data are available.
We will use standardised mean differences for continuous
outcomesand risk ratios for dichotomousoutcomes.Wewill calculate
the NNT to benefit and NNT to harm where appropriate. Heteroge-
neity will be interpreted following the Cochrane Handbook.17 Adverse
events will be entered into meta-analyses and calculated using risk
ratios and95%confidence intervals.Where zero events occur in trials,
wewill enter 0.5 intoeachcell of theanalysis.49Wherepossible,wewill
describe any assessment of possible causality of adverse events.
We will conduct comparisons of cannabis vs control, and
CBMs (to include individual cannabinoids) vs control, for each of
our named outcomes to determine efficacy. We will conduct the
following 4 primary analyses, which will include all trials,
conducted with a subgroup analysis of low risk of bias vs
unclear/high risk of bias trials, at 2 time points:
(1) Cannabis vs control at short-term follow-up (between up to 7
days after administration);
(2) Cannabis vs control at long-term follow-up (greater than or
equal to 7 days after administration);
(3) Cannabis-based medicine vs control at short-term follow-up
(between up to 7 days after administration); and
(4) Cannabis-based medicine vs control at long-term follow-up
(greater than or equal to 7 days after administration).
We will conduct sensitivity analyses where appropriate to
investigate the impact of risk of bias and study quality.
3.12.1. Subgroup analyses
In addition, where enough data are available, we will conduct the
following subgroup analyses at 2 time points outlined above:
(1) Age of participants (2–10 years, 11–17 years, 18–64 years,
and older than 65 years);
(2) The drug subtype under investigation for cannabis and CBMs;
(3) Type of comparator;
(4) Route of administration;
(5) Dose of treatment;
(6) Type of pain experienced (acute, neuropathic pain, fibromyal-
gia, musculoskeletal pain, headache/migraine, etc.); and
(7) Cannabis or CBM administered adjunctively vs nonadjunc-
tively to other medicines.
4. Discussion
This overview review and review of RCTs forms part of a wider
programme ofwork requested by the International Association for
the Study of Pain (www.iasp-pain.org) to examine the role of
cannabinoid, cannabis, and CBMs in the treatment of pain. It is
intended that the 2 products can be used to help in future study
design and reporting, to ensure the efficient and appropriate
design, conduct, and analysis of clinical trials to the benefit of
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people with pain. We will provide recommendations based on
evidence-based findings from these reviews on the clinical use of
cannabis for people with pain.
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